(RTTNews) - Shares of Corvus Pharmaceuticals Inc. (CRVS) surged in the pre-market trading on Monday after the company unveiled positive results from an early stage study of its developing COVID-19 treatment. In the pre-market trading, CRVS was trading at $6.08, up $2.01 or 49.39 percent. "We continue to see consistent, promising results with CPI-006 in hospitalized COVID-19 patients...We are also exploring the potential use in combination with preventative vaccines under development by third parties to enhance and prolong immunity," said Richard Miller,, president and chief executive officer of Corvus.